{
    "data": [
        {
            "id": "4396380",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-28T02:31:19-05:00",
                "isLockedPro": false,
                "commentCount": 280,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna Could Nosedive On Insider Sales",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "306404",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4396380-moderna-nosedive-on-insider-sales"
            }
        },
        {
            "id": "4394756",
            "type": "article",
            "attributes": {
                "publishOn": "2020-12-15T06:39:23-05:00",
                "isLockedPro": false,
                "commentCount": 175,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: The COVID-19 Upside Appears Priced In",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "304901",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4394756-moderna-covidminus-19-upside-appears-priced-in"
            }
        },
        {
            "id": "4390714",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-20T15:34:12-05:00",
                "isLockedPro": false,
                "commentCount": 158,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: I Don't Agree Excellent COVID-19 Vaccine Catalysts Already Baked Into Share Price",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "301741",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4390714-moderna-i-dont-agree-excellent-covidminus-19-vaccine-catalysts-already-baked-share-price"
            }
        },
        {
            "id": "4383667",
            "type": "article",
            "attributes": {
                "publishOn": "2020-11-01T01:11:36-04:00",
                "isLockedPro": false,
                "commentCount": 159,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: Covid Vaccine Is A Front Runner But Chances Of Approval May Not Be Better Than 50:50",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104985",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "298777",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4383667-moderna-covid-vaccine-is-front-runner-chances-of-approval-may-not-be-better-50-50"
            }
        },
        {
            "id": "4382848",
            "type": "article",
            "attributes": {
                "publishOn": "2020-10-29T20:16:59-04:00",
                "isLockedPro": false,
                "commentCount": 53,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "VBI Vaccines: A Novice In COVID-19 Vaccine Race Outshines Moderna",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104895",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "298583",
                            "type": "sentiment"
                        },
                        {
                            "id": "298584",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4382848-vbi-vaccines-novice-in-covidminus-19-vaccine-race-outshines-moderna"
            }
        },
        {
            "id": "4377077",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-30T17:27:59-04:00",
                "isLockedPro": false,
                "commentCount": 395,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "COVID-19 Vaccine Race Heats Up: Moderna Faces Off Against Pfizer And BioNTech",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "294590",
                            "type": "sentiment"
                        },
                        {
                            "id": "294591",
                            "type": "sentiment"
                        },
                        {
                            "id": "294592",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4377077-covidminus-19-vaccine-race-heats-up-moderna-faces-off-against-pfizer-and-biontech"
            }
        },
        {
            "id": "4376795",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-29T08:53:32-04:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Investors Should Buy Moderna Instead Of Inovio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "294309",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4376795-why-investors-should-buy-moderna-instead-of-inovio"
            }
        },
        {
            "id": "4374746",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-16T15:58:24-04:00",
                "isLockedPro": false,
                "commentCount": 157,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: All Signs Point To An Impending Rally",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104895",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "292614",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4374746-moderna-all-signs-point-to-impending-rally"
            }
        },
        {
            "id": "4372162",
            "type": "article",
            "attributes": {
                "publishOn": "2020-09-02T15:27:31-04:00",
                "isLockedPro": false,
                "commentCount": 204,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Who Is Ahead In The COVID-19 Vaccine Race?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "290847",
                            "type": "sentiment"
                        },
                        {
                            "id": "290848",
                            "type": "sentiment"
                        },
                        {
                            "id": "290849",
                            "type": "sentiment"
                        },
                        {
                            "id": "290850",
                            "type": "sentiment"
                        },
                        {
                            "id": "290851",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4372162-who-is-ahead-in-covidminus-19-vaccine-race"
            }
        },
        {
            "id": "4371298",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-28T03:37:12-04:00",
                "isLockedPro": false,
                "commentCount": 132,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Moderna Will Fare After Posting Strong Clinical Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "290152",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4371298-how-moderna-will-fare-after-posting-strong-clinical-results"
            }
        },
        {
            "id": "4370116",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-21T09:42:19-04:00",
                "isLockedPro": false,
                "commentCount": 156,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna Is A High Risk, High Reward Short With A Lot Of Success Priced In And Significant Competition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "95516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "289051",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4370116-moderna-is-high-risk-high-reward-short-lot-of-success-priced-in-and-significant-competition"
            }
        },
        {
            "id": "4367306",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-10T21:01:11-04:00",
                "isLockedPro": false,
                "commentCount": 140,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Moderna Is Moving Nowhere For Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "287660",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4367306-why-moderna-is-moving-nowhere-for-now"
            }
        },
        {
            "id": "4367241",
            "type": "article",
            "attributes": {
                "publishOn": "2020-08-10T16:39:26-04:00",
                "isLockedPro": false,
                "commentCount": 128,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "T Cell Responses To Coronavirus Vaccines Are In The Interest Of National Security",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "287515",
                            "type": "sentiment"
                        },
                        {
                            "id": "287516",
                            "type": "sentiment"
                        },
                        {
                            "id": "287517",
                            "type": "sentiment"
                        },
                        {
                            "id": "287518",
                            "type": "sentiment"
                        },
                        {
                            "id": "287549",
                            "type": "sentiment"
                        },
                        {
                            "id": "287521",
                            "type": "sentiment"
                        },
                        {
                            "id": "287522",
                            "type": "sentiment"
                        },
                        {
                            "id": "287523",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4367241-t-cell-responses-to-coronavirus-vaccines-are-in-interest-of-national-security"
            }
        },
        {
            "id": "4362024",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-29T18:01:31-04:00",
                "isLockedPro": false,
                "commentCount": 80,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: $30 Billion Market Capitalization Is Rich",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "286053",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4362024-moderna-30-billion-market-capitalization-is-rich"
            }
        },
        {
            "id": "4360991",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-27T10:04:54-04:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna, Inc.: The Recent Pullback Is No Reason To Accumulate",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104895",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "285694",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4360991-moderna-inc-recent-pullback-is-no-reason-to-accumulate"
            }
        },
        {
            "id": "4360992",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-27T09:36:53-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna's Patent Snub, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "285587",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4360992-modernas-patent-snub-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4359377",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-20T11:08:58-04:00",
                "isLockedPro": false,
                "commentCount": 66,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna Stock Might Not Be The Play For Moderna Bulls",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24594",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "284681",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4359377-moderna-stock-might-not-be-play-for-moderna-bulls"
            }
        },
        {
            "id": "4358509",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-14T22:59:48-04:00",
                "isLockedPro": false,
                "commentCount": 247,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Moderna May Have Trouble Trading Above $100",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "284016",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4358509-why-moderna-may-trouble-trading-above-100"
            }
        },
        {
            "id": "4357964",
            "type": "article",
            "attributes": {
                "publishOn": "2020-07-12T04:52:25-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna's COVID-19 Vaccine And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "283399",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4357964-modernas-covidminus-19-vaccine-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4355566",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-25T06:37:20-04:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna Has Speculative Upside On Continued Vaccine Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105629",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "281397",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4355566-moderna-speculative-upside-on-continued-vaccine-success"
            }
        },
        {
            "id": "4352516",
            "type": "article",
            "attributes": {
                "publishOn": "2020-06-08T10:07:42-04:00",
                "isLockedPro": false,
                "commentCount": 18,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: July Updates For mRNA-1273 And Some Investment Strategies",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "278564",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4352516-moderna-july-updates-for-mrnaminus-1273-and-investment-strategies"
            }
        },
        {
            "id": "4349354",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-21T13:46:49-04:00",
                "isLockedPro": false,
                "commentCount": 352,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna's COVID-19 Vaccine Development Neglects The Importance Of T Cells",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56012",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273677",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4349354-modernas-covidminus-19-vaccine-development-neglects-importance-of-t-cells"
            }
        },
        {
            "id": "4349086",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-20T15:13:28-04:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna Market Theory",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "56062",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276329",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4349086-moderna-market-theory"
            }
        },
        {
            "id": "4349015",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-20T12:08:07-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Don't Get Keen On Moderna, It's Going To Be Difficult",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24643",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276242",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4349015-dont-get-keen-on-moderna-going-to-be-difficult"
            }
        },
        {
            "id": "4348919",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-20T07:25:52-04:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "First Results From Moderna's Coronavirus Vaccine",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "276350",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4348919-first-results-from-modernas-coronavirus-vaccine"
            }
        },
        {
            "id": "4348571",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-18T17:14:58-04:00",
                "isLockedPro": false,
                "commentCount": 80,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: Answering The COVID-19 Call",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101378",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "275534",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4348571-moderna-answering-covidminus-19-call"
            }
        },
        {
            "id": "4346031",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-11T10:06:52-04:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Happens Next To Moderna Stock After That Big Rally",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274871",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4346031-what-happens-next-to-moderna-stock-after-big-rally"
            }
        },
        {
            "id": "4345615",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-10T08:34:23-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna Phase 2 Approved, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "274628",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4345615-moderna-phase-2-approved-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4342713",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-04T11:57:48-04:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna, Inc.: Trial Uncertainty Risks Peak Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104895",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273739",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342713-moderna-inc-trial-uncertainty-risks-peak-valuation"
            }
        },
        {
            "id": "4342415",
            "type": "article",
            "attributes": {
                "publishOn": "2020-05-03T05:02:13-04:00",
                "isLockedPro": false,
                "commentCount": 26,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna Covid Drug Production Deal, And Other News: The Good, Bad And Ugly Of Biopharma",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "273537",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4342415-moderna-covid-drug-production-deal-and-news-good-bad-and-ugly-of-biopharma"
            }
        },
        {
            "id": "4340366",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-28T11:15:00-04:00",
                "isLockedPro": false,
                "commentCount": 83,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Adam Feuerstein Talks COVID-19 Treatments And Vaccines On Alpha Trader",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105447",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "579361",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4340366-adam-feuerstein-talks-covidminus-19-treatments-and-vaccines-on-alpha-trader"
            }
        },
        {
            "id": "4338529",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-20T10:24:59-04:00",
                "isLockedPro": false,
                "commentCount": 270,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: Promising COVID-19 Vaccine Does Not Justify Its Current Market Cap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105452",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "270891",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4338529-moderna-promising-covidminus-19-vaccine-not-justify-current-market-cap"
            }
        },
        {
            "id": "4336914",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-09T15:18:22-04:00",
                "isLockedPro": false,
                "commentCount": 51,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: A $12 Billion Brand Built On Hope And mRNA",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103050",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "269667",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4336914-moderna-12-billion-brand-built-on-hope-and-mrna"
            }
        },
        {
            "id": "4336492",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-07T14:38:27-04:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Moderna's Prospects Still Look Great",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "269330",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4336492-why-modernas-prospects-still-look-great"
            }
        },
        {
            "id": "4335850",
            "type": "article",
            "attributes": {
                "publishOn": "2020-04-04T07:30:00-04:00",
                "isLockedPro": false,
                "commentCount": 85,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Coronavirus Roundtable - Strains And Hopes In The Healthcare Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102107",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4335850-coronavirus-roundtable-strains-and-hopes-in-healthcare-sector"
            }
        },
        {
            "id": "4334205",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-25T15:30:52-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "USA: A Brutal Post-Coronavirus Economic Reset",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75975",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "267218",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4334205-usa-brutal-post-coronavirus-economic-reset"
            }
        },
        {
            "id": "4332654",
            "type": "article",
            "attributes": {
                "publishOn": "2020-03-17T23:56:14-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Moderna Shares Have Further Upside Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "265854",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4332654-why-moderna-shares-upside-ahead"
            }
        },
        {
            "id": "4327663",
            "type": "article",
            "attributes": {
                "publishOn": "2020-02-27T08:27:08-05:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Shares Of Moderna Soared",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "263090",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4327663-why-shares-of-moderna-soared"
            }
        },
        {
            "id": "4323804",
            "type": "article",
            "attributes": {
                "publishOn": "2020-02-13T08:28:37-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Moderna: A Reversal Of Fortunes Merits A Reality Check",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104895",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "261217",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4323804-moderna-reversal-of-fortunes-merits-reality-check"
            }
        },
        {
            "id": "4319443",
            "type": "article",
            "attributes": {
                "publishOn": "2020-01-28T08:50:04-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons To Buy Moderna",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22786",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "258198",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "586083",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4319443-3-reasons-to-buy-moderna"
            }
        }
    ]
}